0001209191-23-041355.txt : 20230705 0001209191-23-041355.hdr.sgml : 20230705 20230705202041 ACCESSION NUMBER: 0001209191-23-041355 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230703 FILED AS OF DATE: 20230705 DATE AS OF CHANGE: 20230705 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nuss John CENTRAL INDEX KEY: 0001874108 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40928 FILM NUMBER: 231071683 MAIL ADDRESS: STREET 1: C/O VENTYX BIOSCIENCES, INC. STREET 2: 332 ENCINITAS BLVD. SUITE 200 CITY: ENCINITAS STATE: CA ZIP: 92024 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ventyx Biosciences, Inc. CENTRAL INDEX KEY: 0001851194 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832996852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 662 ENCINITAS BLVD., STE. 250 CITY: ENCINITAS STATE: CA ZIP: 92024 BUSINESS PHONE: (858) 945-2393 MAIL ADDRESS: STREET 1: 662 ENCINITAS BLVD., STE. 250 CITY: ENCINITAS STATE: CA ZIP: 92024 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-07-03 0 0001851194 Ventyx Biosciences, Inc. VTYX 0001874108 Nuss John C/O VENTYX BIOSCIENCES, INC. ENCINITAS BLVD, SUITE 250 ENCINITAS CA 92024 0 1 0 0 Chief Scientific Officer 0 Common Stock 2023-07-03 4 M 0 20000 0.20 A 264815 D Common Stock 2023-07-03 4 S 0 327 33.5442 D 264488 D Common Stock 2023-07-03 4 S 0 142 34.7231 D 264346 D Common Stock 2023-07-03 4 S 0 20 35.2737 D 264326 D Common Stock 2023-07-03 4 S 0 2266 38.3193 D 262060 D Common Stock 2023-07-03 4 S 0 1563 39.3348 D 260497 D Common Stock 2023-07-03 4 S 0 15682 39.9643 D 244815 D Stock Option (right to buy) 0.20 2023-07-03 4 M 0 20000 0.00 D 2030-05-01 Common Stock 20000 26778 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2022. Represents the weighted average share price of an aggregate total of 327 shares sold in the price range of $33.28 to $34.1123. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average share price of an aggregate total of 142 shares sold in the price range of $34.2706 to $35.2163. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average share price of an aggregate total of 2,266 shares sold in the price range of $37.9611 to $38.9601. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average share price of an aggregate total of 1,563 shares sold in the price range of $38.9668 to $39.6514. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average share price of an aggregate total of 15,682 shares sold in the price range of $39.70 to $40.0506. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Option granted under pursuant to the Issuer's 2019 Equity Incentive Plan, as amended (the "2019 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2019 Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 1, 2020. /s/ Christopher Krueger, as Attorney-in-Fact 2023-07-05